Published in Blood Weekly, November 1st, 1999
N. Murayama and colleagues, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan, and colleagues performed a study to assess the tolerability, pharmacokinetic and pharmacodynamic properties of DX-9065a, a novel, low-molecule, specific factor Xa inhibitor in healthy male volunteers.
"DX-9065a was intravenously administered to healthy male Japanese volunteers at doses of 0.625 to 30 mg. The drug concentrations in plasma and urine were measured and pharmacokinetic parameters were calculated. Coagulation time and bleeding time were also measured, Murayama et...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.